Nuclear receptor binding agents
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 28, 2014
Grant Date -
Jun 21, 2012
app pub date -
Jan 31, 2012
filing date -
Nov 28, 2005
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully